Autonomic nervous system and risk factors for vascular disease. Effects of autonomic unbalance in Schizophrenia and Parkinson's disease

被引:10
作者
Scigliano, Giulio [1 ]
Ronchetti, Gabriele [2 ]
Girotti, Floriano [1 ]
机构
[1] Ist Nazl Neurol Carlo Besta, I-20133 Milan, Italy
[2] Univ Milan, IRCCS Fdn Osped Maggiore, Dino Ferrari Ctr, Dept Neurol Sci, Milan, Italy
关键词
Schizophrenia; Parkinson; cholesterol diabetes; antipsychotic; levodopa;
D O I
10.1007/s10072-008-0853-1
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Alterations of the cardiovascular system and of the glucose and lipid metabolism can represent important factors of vascular risk. The autonomic nervous system, through its two efferent branches, the parasympathetic-cholinergic and the sympathetic-adrenergic, plays an important role in the control of the cardiovascular activity and of the glucose and lipid metabolism, and its impaired working can interfere with these functions. An increased sympathetic activity and an increased frequency of diabetes, dyslipidemia, hypertension and obesity have been reported in untreated schizophrenic patients, and a further worsening of these vascular risk factors has been signalled as a side effect of treatment with neuroleptic drugs. The opposite is observed in Parkinson's disease, where the reduced autonomic activity induced by the illness is associated with a decreased frequency of vascular risk factors, and their occurrence is further reduced by the treatment with dopaminergic drugs.
引用
收藏
页码:15 / 21
页数:7
相关论文
共 75 条
[1]   Autonomic regulation of islet hormone secretion -: Implications for health and disease [J].
Ahrén, B .
DIABETOLOGIA, 2000, 43 (04) :393-410
[2]   The cephalic insulin response to meal ingestion in humans is dependent on both cholinergic and noncholinergic mechanisms and is important for postprandial glycemia [J].
Ahrén, B ;
Holst, JJ .
DIABETES, 2001, 50 (05) :1030-1038
[3]   DECREASE IN DOPAMINE, ITS METABOLITES AND NORADRENALINE IN CEREBROSPINAL-FLUID OF SCHIZOPHRENIC-PATIENTS AFTER WITHDRAWAL OF LONG-TERM NEUROLEPTIC TREATMENT [J].
BAGDY, G ;
PERENYI, A ;
FRECSKA, E ;
REVAI, K ;
PAPP, Z ;
FEKETE, MIK ;
ARATO, M .
PSYCHOPHARMACOLOGY, 1985, 85 (01) :62-64
[4]   Loss of efferent vagal activity in acute schizophrenia [J].
Bär, KJ ;
Letzsch, A ;
Jochum, T ;
Wagner, G ;
Greiner, W ;
Sauer, H .
JOURNAL OF PSYCHIATRIC RESEARCH, 2005, 39 (05) :519-527
[5]   RENIN-ALDOSTERONE SYSTEM IN PARKINSONS DISEASE [J].
BARBEAU, A ;
GILLOJOF.L ;
BOUCHER, R ;
NOWACZYNSKI, W ;
GENEST, J .
SCIENCE, 1969, 165 (3890) :291-+
[6]   SURVIVAL AND CAUSE OF DEATH IN A COHORT OF PATIENTS WITH PARKINSONISM - POSSIBLE CLUES TO ETIOLOGY [J].
BENSHLOMO, Y ;
MARMOT, MG .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1995, 58 (03) :293-299
[7]   EFFECT OF CIGARETTE-SMOKING ON LIPIDS, LIPOPROTEINS, BLOOD-COAGULATION, FIBRINOLYSIS AND CELLULAR COMPONENTS OF HUMAN-BLOOD [J].
BILLIMORIA, JD ;
POZNER, H ;
METSELAAR, B ;
BEST, FW ;
JAMES, DCO .
ATHEROSCLEROSIS, 1975, 21 (01) :61-76
[8]   Biologic rhythms and Parkinson's disease: a chronopharmacologic approach to considering fluctuations in function [J].
Bruguerolle, B ;
Simon, N .
CLINICAL NEUROPHARMACOLOGY, 2002, 25 (04) :194-201
[9]   Adrenocortical, autonomic, and inflammatory causes of the metabolic syndrome - Nested case-control study [J].
Brunner, EJ ;
Hemingway, H ;
Walker, BR ;
Page, M ;
Clarke, P ;
Juneja, M ;
Shipley, MJ ;
Kumari, M ;
Andrew, R ;
Seckl, JR ;
Papadopoulos, A ;
Checkley, S ;
Rumley, A ;
Lowe, GDO ;
Stansfeld, SA ;
Marmot, MG .
CIRCULATION, 2002, 106 (21) :2659-2665
[10]  
CARMICHAEL SW, 1988, NEW ENGL J MED, V318, P254